Procyon Advisors LLC Boosts Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Procyon Advisors LLC boosted its stake in Zoetis Inc. (NYSE:ZTS) by 1.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,712 shares of the company’s stock after purchasing an additional 63 shares during the quarter. Procyon Advisors LLC’s holdings in Zoetis were worth $768,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in ZTS. Darwin Wealth Management LLC purchased a new stake in shares of Zoetis in the third quarter worth about $31,000. First Personal Financial Services purchased a new stake in shares of Zoetis during the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP bought a new position in shares of Zoetis during the 3rd quarter valued at approximately $33,000. Dunhill Financial LLC grew its holdings in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Quarry LP increased its position in Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Stifel Nicolaus lowered their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. upped their price objective on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. UBS Group started coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. Finally, Leerink Partners initiated coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $211.89.

Zoetis Stock Performance

Shares of Zoetis stock opened at $166.01 on Friday. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53. The company has a market capitalization of $74.90 billion, a PE ratio of 31.20, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89. The stock’s fifty day moving average is $170.93 and its two-hundred day moving average is $179.95. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm’s revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.36 EPS. As a group, analysts expect that Zoetis Inc. will post 5.91 earnings per share for the current year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.20%. The ex-dividend date of this dividend is Tuesday, January 21st. This is an increase from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s payout ratio is currently 32.52%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.